 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the CchekTM liquid biopsy technology. 